De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia
Amro El-Ghammaz, Abdelwahed, Essam, Mostafa, Nevine N, Mansour, Dina A,
To determine the prognostic impact of de novo deletion 17p13.1 (17p-) in previously untreated chronic lymphocytic leukemia (CLL) patients, we prospectively studied the outcome of 71 treatment-naïve CLL patients. About 18.3 % of them had 17p- detected by interphase fluorescent in situ hybridization (FISH) at diagnosis. There was statistically significant difference between 17p- negative and positive patients as regards 2-year overall survival [OS] (89.7 vs. 53.8 %, respectively; P = 0.001). On the other hand, 2-year progression-free survival [PFS] was also significantly higher in 17p- negative group than in 17p- positive one (82.8 vs. 23.1 %, respectively; P < 0.001). On univariate analysis for OS, 17p- positivity was significantly associated with shorter OS (P = 0.003). However, when we performed multivariate analysis, 17p- lost its significant impact. On the other hand, 17p- positivity was a significant risk factor for PFS in both univariate and multivariate analyses [independent risk factor] (P < 0.001 and P = 0.02, respectively). So, 17p- is a predictor for disease progression, but not for survival in CLL patients.
|Title||De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia||Authors||Amro El-Ghammaz ; Abdelwahed, Essam; Mostafa, Nevine N; Mansour, Dina A||Keywords||Chronic lymphocytic leukemia; De novo; Deletion 17p13.1; Overall survival; Progression-free survival||Issue Date||Nov-2015||Publisher||Springer||Journal||Clinical and experimental medicine||Volume||15||Issue||4||Start page||493||End page||499||ISSN||1591-9528||DOI||10.1007/s10238-014-0317-2||PubMed ID||25300358|
Recommend this item
Similar Items from Core Recommender Database
Citations 2 in pubmed
Citations 1 in scopus
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.